What is elucidating
Jason holds degrees from the University of Wisconsin-Stevens Point (B. Stanislav holds a MBA in Banking and Finance from the University of New York in Prague.Jakub has also worked and was closely involved with our partner company Areko as a director and advisor to the executive team. Michal cofounded Machavert and is responsible for investor relations and as CFO is responsible for controlling and budgeting.
Phospho lipids modulate a great number of immune related events, such as lymphocyte proliferation, cytokine production, as well as phagocytosis.Jakub has also worked and was closely involved with our partner company Areko as a director and advisor to the executive team. Neal Goodwin acts as our Chief Science Officer responsible for all research and development programs. in Microbiology from The University of Montana and served a postdoctoral fellowship in functional genomics at The Jackson Laboratory with John Schimenti (now at Cornell).Neal recently served as Vice President, Corporate Research Development for Champions Oncology (NASDAQ: CSBR) where his responsibilities included development of a patient derived tumorgraft pharmacology portfolio for personalized oncology and translational oncology solutions. Greg focuses on discovery of new phospholipids and other small molecules and their modifications to create prospect candidates for drug development.He previously served as the Director, Research and Development and the founding Program Director of JAX Cancer Services where he established a patient derived tumor biology program in collaboration with over 20 clinical cancer centers. Goodwin is a co-founder and a former Chief Scientific Officer of Pro NAi Therapeutics (now Sierra Oncology; NASDAQ: SRRA) and he has served as a senior research scientist in genomic technologies at Pharmacia. Greg has over 15 years of experience in medicinal chemistry and has worked at research positions both at small and large organizations such as Abbot Laboratories, Array Biopharma and lastly as an Associate Director at the Colorado Center for Drug Discovery at Colorado State University.Greg has been involved in almost all aspects of preclinical drug discovery and has worked in the areas of cancer, inflammation, pain and anti-virals.
Machavert is a bio-pharmaceutical company that develops new, first-in-class therapeutics that will harness the power of the human body to treat cancer and autoimmune diseases.